Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

PACB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacific Biosciences of California, Inc.

PACB

NEW YORK, NY / ACCESSWIRE / August 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws.

On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026. PACB attributed it to "an increasing number of customers delay instrument purchases and we experienced some unexpected softness in consumable shipments." Analysts reacting to the preannounced results were surprised by the significance of the miss and resulting guide down, noting it was "alarming" and "far worse than we expected."

Following this news, PACB's stock price fell by $1.44 per share to close at $1.40 per share. To obtain additional information, go to:

https://zlk.com/pslra-1/pacific-biosciences-of-california-inc-lawsuit-submission-form?prid=94933&wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.


WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP



View the original press release on accesswire.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today